Trials / Unknown
UnknownNCT04977960
Efficacy of Canrenone as add-on Treatment in Moderate to Severe ARDS in COVID-19
MINECRAFT Study: MINEralcorticoid Receptor Antagonism With CanRenone As eFfective Treatment in Moderate to Severe ARDS in COVID-19, a Phase 2 Clinical Trial.
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 180 (estimated)
- Sponsor
- Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The main aim of the study is to estimate the potential efficacy of i.v. canrenone as add-on therapy on maximal medical treatment versus maximal medical treatment alone in treating moderate-to-severe ARDS due to SARS-CoV-2.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Potassium Canrenoate | potassium canrenoate for 7 days in addition to maximal medical treatment |
Timeline
- Start date
- 2022-09-01
- Primary completion
- 2023-05-01
- Completion
- 2023-12-01
- First posted
- 2021-07-27
- Last updated
- 2022-05-20
Source: ClinicalTrials.gov record NCT04977960. Inclusion in this directory is not an endorsement.